Bank of New York Mellon Corp boosted its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 4.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,786 shares of the biopharmaceutical company’s stock after acquiring […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and DMK Pharmaceuticals (NASDAQ:DMK – Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership. Insider & Institutional Ownership 79.9% of Madrigal Pharmaceuticals […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and DMK Pharmaceuticals (NASDAQ:DMK – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Risk and Volatility Madrigal Pharmaceuticals has a beta […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) had its price objective hoisted by equities researchers at Piper Sandler from $305.00 to $336.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price target suggests a potential upside of 45.91% […]